Published in Urology on March 01, 2003
Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones (2005) 5.22
The HSP70 family and cancer. Carcinogenesis (2013) 2.06
Hsp70 in cancer: back to the future. Oncogene (2014) 1.03
The human HSP70 family of chaperones: where do we stand? Cell Stress Chaperones (2016) 0.95
The role of heat shock proteins in bladder cancer. Nat Rev Urol (2013) 0.91
The complex function of hsp70 in metastatic cancer. Cancers (Basel) (2013) 0.87
Stress Inducibility of SIRT1 and Its Role in Cytoprotection and Cancer. Genes Cancer (2013) 0.83
Anchoring of both PKA-RIIα and 14-3-3θ regulates retinoic acid induced 16 mediated phosphorylation of heat shock protein 70. Oncotarget (2015) 0.81
High expression of heat shock protein 105 predicts a favorable prognosis for patients with urinary bladder cancer treated with radical cystectomy. Mol Clin Oncol (2013) 0.79
Expression of heat shock proteins in premalignant and malignant urothelial lesions of bovine urinary bladder. Cell Stress Chaperones (2012) 0.78
Polymorphisms of PRLHR and HSPA12A and risk of gastric and colorectal cancer in the Chinese Han population. BMC Gastroenterol (2015) 0.77
Heat shock proteins at the crossroads between cancer and Alzheimer's disease. Biomed Res Int (2014) 0.76
Knock-down of Hdj2/DNAJA1 co-chaperone results in an unexpected burst of tumorigenicity of C6 glioblastoma cells. Oncotarget (2016) 0.75
Heat shock protein 70 downregulation inhibits proliferation, migration and tumorigenicity in hepatocellular carcinoma cells. Oncol Lett (2017) 0.75
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol (2011) 7.46
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res (2006) 2.35
The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci U S A (2009) 2.29
Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol (2011) 2.20
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res (2008) 2.18
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 2.14
Access to cancer drugs: local autonomy or local tyranny? Br J Hosp Med (Lond) (2008) 2.03
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol (2011) 1.82
Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther (2008) 1.78
Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol (2008) 1.70
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res (2012) 1.67
Assessment and management of dysphagia in patients with head and neck cancer who receive radiotherapy in the United Kingdom - a web-based survey. Oral Oncol (2011) 1.58
Making sense of post-treatment surveillance in head and neck cancer: when and what of follow-up. Cancer Treat Rev (2009) 1.58
Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res (2008) 1.56
Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study. Int J Radiat Oncol Biol Phys (2010) 1.55
CD3 limits the efficacy of TCR gene therapy in vivo. Blood (2011) 1.55
Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene (2004) 1.54
Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys (2006) 1.53
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res (2010) 1.53
Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res (2009) 1.50
99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer. J Nucl Med (2002) 1.44
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res (2008) 1.44
Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res (2002) 1.42
Should the treatment paradigms for oral and oropharyngeal cancers be changed now: the role of human papilloma virus? ANZ J Surg (2011) 1.40
Improving outcomes in early prostate cancer: Part II--neoadjuvant treatment. BJU Int (2006) 1.38
FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res (2010) 1.31
Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev (2005) 1.31
Impact of analytical bias in metabonomic studies of human blood serum and plasma. Anal Chem (2006) 1.29
Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer (2010) 1.29
Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol (2009) 1.25
Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer (2010) 1.18
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer (2011) 1.17
Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene (2004) 1.16
Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. Cancer Res (2004) 1.15
Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther (2008) 1.14
Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res (2002) 1.13
Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res (2011) 1.12
The impact of introducing intensity modulated radiotherapy into routine clinical practice. Radiother Oncol (2005) 1.10
Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer (2012) 1.09
Head and neck cancer in the elderly: an overview on the treatment modalities. Cancer Treat Rev (2008) 1.08
Hemodynamic responses in neural circuitries for detection of visual target and novelty: An event-related fMRI study. Hum Brain Mapp (2007) 1.07
Cadherins: an integral role in inflammatory bowel disease and mucosal restitution. J Gastroenterol (2004) 1.06
Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review. Crit Rev Oncol Hematol (2013) 1.05
Human leptin induces angiogenesis in vivo. Cytokine (2008) 1.04
Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Mod Pathol (2012) 1.03
Validation of the Sydney Swallow Questionnaire (SSQ) in a cohort of head and neck cancer patients. Oral Oncol (2010) 0.99
Analysis of stromal-epithelial interactions in prostate cancer identifies PTPCAAX2 as a potential oncogene. Cancer Lett (2002) 0.99
The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PLoS One (2012) 0.98
Intensity Modulated Radiotherapy (IMRT) in locally advanced thyroid cancer: acute toxicity results of a phase I study. Radiother Oncol (2007) 0.98
Targeting the HOX/PBX dimer in breast cancer. Breast Cancer Res Treat (2012) 0.97
Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. J Pathol (2009) 0.97
Dosimetric explanations of fatigue in head and neck radiotherapy: an analysis from the PARSPORT Phase III trial. Radiother Oncol (2012) 0.97
Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Clin Cancer Res (2006) 0.97
Comprehensive review of small bowel metastasis from head and neck squamous cell carcinoma. Oral Oncol (2010) 0.97
Clinical significance of serum levels of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in gastric cancer patients. Am J Gastroenterol (2003) 0.97
Endo180 expression with cofunctional partners MT1-MMP and uPAR-uPA is correlated with prostate cancer progression. Eur J Cancer (2008) 0.96
FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth. Cancer Res (2010) 0.96
Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer. Int J Cancer (2012) 0.96
Implications of understanding cancer stem cell (CSC) biology in head and neck squamous cell cancer. Oral Oncol (2011) 0.96
Assessment of a customised immobilisation system for head and neck IMRT using electronic portal imaging. Radiother Oncol (2005) 0.96
Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours. Endocr Relat Cancer (2009) 0.95
Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. Int J Cancer (2012) 0.95
The value of magnetic resonance imaging in target volume delineation of base of tongue tumours--a study using flexible surface coils. Radiother Oncol (2010) 0.94
Swallowing outcomes following Intensity Modulated Radiation Therapy (IMRT) for head & neck cancer - a systematic review. Oral Oncol (2010) 0.94
A modified inflammatory bowel disease questionnaire and the Vaizey Incontinence questionnaire are more sensitive measures of acute gastrointestinal toxicity during pelvic radiotherapy than RTOG grading. Int J Radiat Oncol Biol Phys (2006) 0.94
Dose-response analysis of parotid gland function: what is the best measure of xerostomia? Radiother Oncol (2013) 0.93
Novel targeted radiosensitisers in cancer treatment. Curr Drug Discov Technol (2009) 0.93
Correlation between dose to the pharyngeal constrictors and patient quality of life and late dysphagia following chemo-IMRT for head and neck cancer. Radiother Oncol (2009) 0.93
Targeted radiosensitization by the Chk1 inhibitor SAR-020106. Int J Radiat Oncol Biol Phys (2012) 0.93
Quality of life and outcomes research in head and neck cancer: a review of the state of the discipline and likely future directions. Cancer Treat Rev (2009) 0.92
Tracheo-oesophageal party wall thickness in laryngectomised patients in India: implications for surgical voice restoration. J Surg Oncol (2010) 0.92
Doctors should not discuss resuscitation with terminally ill patients: FOR. BMJ (2003) 0.92
A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. Radiother Oncol (2007) 0.92
Oncolytic viruses in radiation oncology. Radiother Oncol (2011) 0.92
Immunotherapeutic potential of oncolytic virotherapy. Lancet Oncol (2008) 0.92
Intensity-modulated radiotherapy improves target coverage, spinal cord sparing and allows dose escalation in patients with locally advanced cancer of the larynx. Radiother Oncol (2004) 0.92
Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther (2015) 0.92
Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours. Eur J Nucl Med Mol Imaging (2010) 0.92
Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation. Cancer Res (2013) 0.91
Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. Int J Cancer (2009) 0.91
Clinical significance of serum and urinary c-erbB-2 levels in colorectal cancer. Cancer Lett (2002) 0.91
Reducing the risk of xerostomia and mandibular osteoradionecrosis: the potential benefits of intensity modulated radiotherapy in advanced oral cavity carcinoma. Med Dosim (2008) 0.91
Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers. Int J Radiat Oncol Biol Phys (2011) 0.90
Early chemotherapy in prostate cancer. Nat Clin Pract Urol (2008) 0.90
The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. Expert Opin Ther Targets (2005) 0.90
Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer. Radiother Oncol (2012) 0.90
Electroglottographic comparison of voice outcomes in patients with advanced laryngopharyngeal cancer treated by chemoradiotherapy or total laryngectomy. Int J Radiat Oncol Biol Phys (2007) 0.90
Targeting HOX transcription factors in prostate cancer. BMC Urol (2014) 0.89
Novel approaches to improve the therapeutic index of head and neck radiotherapy: an analysis of data from the PARSPORT randomised phase III trial. Radiother Oncol (2012) 0.89
Visualising androgen receptor activity in male and female mice. PLoS One (2013) 0.89
Metabolic signatures of malignant progression in prostate epithelial cells. Int J Biochem Cell Biol (2010) 0.89
Challenges for the future modifications of the TNM staging system for head and neck cancer: case for a new computational model? Cancer Treat Rev (2009) 0.89
The involvement of sphingosine kinase 1 in LPS-induced Toll-like receptor 4-mediated accumulation of HIF-1α protein, activation of ASK1 and production of the pro-inflammatory cytokine IL-6. Immunol Cell Biol (2010) 0.89
Evaluation of the role of 18FDG-PET/CT in radiotherapy target definition in patients with head and neck cancer. Acta Oncol (2008) 0.88
The effect of concomitant chemotherapy on parotid gland function following head and neck IMRT. Radiother Oncol (2013) 0.88
Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy. Clin Cancer Res (2008) 0.88
TGFβ1-Endo180-dependent collagen deposition is dysregulated at the tumour-stromal interface in bone metastasis. J Pathol (2011) 0.87
AGE-modified basement membrane cooperates with Endo180 to promote epithelial cell invasiveness and decrease prostate cancer survival. J Pathol (2014) 0.87
Downregulation of Dickkopf-3 disrupts prostate acinar morphogenesis through TGF-β/Smad signalling. J Cell Sci (2013) 0.87
Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy. Radiother Oncol (2010) 0.87